Directed Th2 polarization via controlled atopic immune activation as a therapeutic strategy in multiple sclerosis

Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by immune cells attacking myelin, resulting in inflammation, demyelination, and progressive neurodegeneration. This process involves specific roles for Th1/Th17 cells and microglia. MS disease-modifying therapies (DMTs) employ various mechanisms, which generally fall under immunomodulation, broad immunosuppression, and immune cell depletion. The more potent therapies often involve immune cell depletion, and nearly all carry an increased risk of EAE infection and, despite their effectiveness, do not guarantee complete disease control or a cure for MS. Epidemiological, immunological, and experimental evidence suggests an inverse relationship between atopic (Th2-mediated) immune states and Th1/Th17-driven autoimmunity in multiple sclerosis. This review proposes a mechanistic framework in which controlled induction of Th2-skewed atopic immune signaling—via deliberate, antigen-specific activation of the allergy cascade—may counteract MS pathogenesis by redirecting immune polarity, suppressing pathogenic effector pathways, and modulating CNS-resident innate immune responses. Furthermore, the review outlines a biological rationale, supporting evidence, theoretical mechanism of action, and translational considerations for this immune redirection strategy, with particular emphasis on mast cell–mediated signaling, cytokine antagonism, and microglial phenotype modulation. Alleamit’s patented hyperallergenic platform provides a mechanistically grounded method for inducing sustained Th2 polarization, while artificial intelligence (AI) assisted immune monitoring can enhance safety, personalization, and therapeutic precision. Collectively, this framework supports immune reprogramming as a viable disease-modifying strategy in MS and establishes a foundation for translational development.